Published in Vaccine Weekly, December 27th, 2000
They report in the Proceedings of the National Academy of Sciences that their vaccines are more potent and efficacious than the conventional BCG vaccine that has been used for almost the last 100 years.
Marcus A. Horwitz and colleagues used the commercially available BCG Connaught and BCG Tice strains to construct two new vaccines that express the M. tuberculosis 30-kDa major secretory protein. They tested the vaccines in the guinea pig model of pulmonary tuberculosis, "a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly